+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: results of a phase II open study

An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: results of a phase II open study

Critical Reviews in Oncology/Hematology 66(1): 75-83

To establish a correlation between a specific MGA category, an appropriate preventively established treatment and clinical outcome in a population of elderly cancer patients. The ultimate goal was to verify whether the appropriate treatment given to elderly cancer patients according to their MGA category could translate into a better clinical outcome assessed as clinical response and toxicity, i.e whether this process might achieve a clinically meaningful impact. We carried out a phase II open, prospective non-randomized study in 75 elderly cancer patients (lung, head and neck, colorectal, gynecologic and breast) hospitalized at the Department of Medical Oncology, University of Cagliari, Italy. All patients underwent MGA evaluation and were assigned to three different categories: fit, intermediate and frail. Thereafter, an appropriate preventively established treatment was administered and the clinical outcome was assessed. The clinical outcome after 3 month treatment was defined on the basis of objective clinical response and toxicity. The difference of clinical outcome in the MGA categories was assessed by ANOVA test. Moreover, the correlation between MGA category and the clinical outcome (clinical response and toxicity) was assessed by Spearman's correlation test. A better clinical response was observed in fit patients as compared both to intermediate and frail patients. Treatment toxicity was comparable in the different MGA categories. The correlation analysis between MGA category, clinical response to treatment and toxicity showed that there was a significant direct correlation with clinical response and no correlation with toxicity. Overall, the regression analysis showed that MGA was predictive of clinical outcome, in the sense that it is truly predictive for clinical response and no predictive for toxicity. Our study demonstrates that the MGA, although time-consuming, is a useful and cost-benefit effective tool to appropriately select elderly cancer patients to be treated effectively in terms of a survival advantage and those who would benefit mainly in terms of improvement of quality of life. Moreover, the treatment preventively established for each MGA category was shown to be adequate and accomplished the most appropriate performances in terms of effectiveness and toxicity.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051476920

Download citation: RISBibTeXText

PMID: 18164209

DOI: 10.1016/j.critrevonc.2007.11.002

Related references

An attempt to correlate comprehensive geriatric assessment (Cga), treatment assignment and clinical outcome in elderly cancer patients: preliminary results of a phase Ii open study. Critical Reviews in Oncology/Hematology 60: S32-S33, 2006

An attempt to correlate "comprehensive geriatric assessment" (CGA), treatment assignment and clinical outcome in elderly cancer patients: Preliminary results of a phase II open study. Journal of Clinical Oncology 24(18_Suppl): 18599-18599, 2016

How much does performance status correlate with multidimensional geriatric assessment in elderly patients with cancer (Epc)?. European Journal of Cancer 31: S255-S256, 1995

Multidimensional geriatric assessment in treatment decision in elderly cancer patients: 6-year experience in an outpatient geriatric oncology service. Critical Reviews in Oncology/Hematology 68(2): 157-164, 2008

PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. European Stroke Journal 3(3): 291-298, 2018

PPT and VES-13 in elderly patients with cancer: evaluation in multidimensional geriatric assessment and prediction of survival. Journal of Geriatric Oncology 5(4): 415-421, 2014

Comprehensive geriatric assessment in elderly cancer patients. Preliminary results from the Italian group of geriatric oncology - GIOGer. Rays 24(2 Suppl. ): 53-57, April-June, 1999

Does the Multidimensional Prognostic Index (MPI), based on a Comprehensive Geriatric Assessment (CGA), predict mortality in cancer patients? Results of a prospective observational trial. Journal of Geriatric Oncology 4(3): 208-217, 2013

Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life. European Journal of Cancer Care 23(3): 401-412, 2014

Geriatric multidimensional assessment for elderly patients with acute respiratory diseases. European Journal of Internal Medicine 25(4): 304-311, 2014

Use of a Comprehensive Geriatric Assessment to Predict Short-Term Postoperative Outcome in Elderly Patients With Colorectal Cancer. Annals of Coloproctology 32(5): 161-169, 2016

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet. Oncology 13(10): E437-E444, 2012

Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. European Journal of Cancer Care 13(5): 424-433, 2004

Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leukemia and Lymphoma 55(1): 38-43, 2014

A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). Bmc Cancer 18(1): 747, 2018